Klaus Langer

机构：University of Münster · ORCID：0000-0002-0203-7478

发表论文 378 篇 · 总被引 13286 次 · h-index 58

代表论文

• Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles (2019 · European Journal of Pharmaceutics and Biopharmaceutics · 被引 186)
• Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells (2019 · Beilstein Journal of Nanotechnology · 被引 81)
• Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study (2019 · Lung Cancer · 被引 44)
• Challenges of nanoparticle albumin bound (nab™) technology: Comparative study of Abraxane® with a newly developed albumin-stabilized itraconazole nanosuspension (2023 · European Journal of Pharmaceutics and Biopharmaceutics · 被引 42)
• Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity (2019 · Beilstein Journal of Nanotechnology · 被引 37)
• Light-responsive polymeric nanoparticles based on a novel nitropiperonal based polyester as drug delivery systems for photosensitizers in PDT (2021 · International Journal of Pharmaceutics · 被引 34)